Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eExos-miRLet7i
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
eExos-miRLet7i is an experimental exosome-based gene delivery tool designed for the treatment of glioblastoma. It consists of engineered exosomes (eExos) that are modified to express retroviral Gag and VSVg proteins, which enhance the packaging efficiency of genetic cargo and facilitate entry into target cells. The therapeutic cargo in this formulation is a plasmid encoding microRNA Let-7i (miR-Let7i), which was identified through high-throughput screening as a potent anti-glioma microRNA. By delivering miR-Let7i directly to glioma stem cells, the therapy aims to inhibit tumor cell proliferation and improve survival. Preclinical studies in mouse models of glioblastoma have demonstrated that eExos-miRLet7i can significantly decrease tumor cell proliferation and, when used in combination with other microRNAs, significantly extend survival.
- Other names
- eExos-miR-Let7ieExos-miR-Let-7ieExos-miR-Let 7iengineered exosomes containing miR-Let7i
Beyond the preview
Go deeper on eExos-miRLet7i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eExos-miRLet7i.